Is Loxo Oncology's Deal With Bayer Bad News?

Is Loxo Oncology's Deal With Bayer Bad News?

After reporting that global biopharma giant Bayer AG (NASDAQOTH: BAYRY) has inked a licensing deal for its most advanced clinical-stage drug, shares in Loxo Oncology (NASDAQ: LOXO) tumbled. Is teaming up with Bayer a bad move for the company?

In this clip from The Motley Fool's Industry Focus: Healthcare, analyst Kristine Harjes and contributor Todd Campbell explain why Loxo Oncology investors were disappointed and what could be next for the company.

A full transcript follows the video.

Continue reading

Source: Fool.com